# Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC

> **NCT05351762** · PHASE2 · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 55 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimotuzumab Combined With Neoadjuvant Chemotherapy

## Key facts

- **NCT ID:** NCT05351762
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2022-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05351762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05351762, "Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05351762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*